Global Cancer Biologics Market Growth (Status and Outlook) 2019-2024
Table of Contents
2019-2024 Global Cancer Biologics Market Report (Status and Outlook)
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Cancer Biologics Market Size 2014-2024
- 2.1.2 Cancer Biologics Market Size CAGR by Region
- 2.2 Cancer Biologics Segment by Type
- 2.2.1 Monoclonal Antibodies
- 2.2.2 Vaccines
- 2.2.3 Cell and Gene Therapy
- 2.2.4 Others
- 2.3 Cancer Biologics Market Size by Type
- 2.3.1 Global Cancer Biologics Market Size Market Share by Type (2014-2019)
- 2.3.2 Global Cancer Biologics Market Size Growth Rate by Type (2014-2019)
- 2.4 Cancer Biologics Segment by Application
- 2.4.1 Hospitals
- 2.4.2 Clinics
- 2.4.3 Others
- 2.5 Cancer Biologics Market Size by Application
- 2.5.1 Global Cancer Biologics Market Size Market Share by Application (2014-2019)
- 2.5.2 Global Cancer Biologics Market Size Growth Rate by Application (2014-2019)
3 Global Cancer Biologics by Players
- 3.1 Global Cancer Biologics Market Size Market Share by Players
- 3.1.1 Global Cancer Biologics Market Size by Players (2017-2019)
- 3.1.2 Global Cancer Biologics Market Size Market Share by Players (2017-2019)
- 3.2 Global Cancer Biologics Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Cancer Biologics by Regions
- 4.1 Cancer Biologics Market Size by Regions
- 4.2 Americas Cancer Biologics Market Size Growth
- 4.3 APAC Cancer Biologics Market Size Growth
- 4.4 Europe Cancer Biologics Market Size Growth
- 4.5 Middle East & Africa Cancer Biologics Market Size Growth
5 Americas
- 5.1 Americas Cancer Biologics Market Size by Countries
- 5.2 Americas Cancer Biologics Market Size by Type
- 5.3 Americas Cancer Biologics Market Size by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Cancer Biologics Market Size by Countries
- 6.2 APAC Cancer Biologics Market Size by Type
- 6.3 APAC Cancer Biologics Market Size by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Cancer Biologics by Countries
- 7.2 Europe Cancer Biologics Market Size by Type
- 7.3 Europe Cancer Biologics Market Size by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Cancer Biologics by Countries
- 8.2 Middle East & Africa Cancer Biologics Market Size by Type
- 8.3 Middle East & Africa Cancer Biologics Market Size by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Global Cancer Biologics Market Forecast
- 10.1 Global Cancer Biologics Market Size Forecast (2019-2024)
- 10.2 Global Cancer Biologics Forecast by Regions
- 10.2.1 Global Cancer Biologics Forecast by Regions (2019-2024)
- 10.2.2 Americas Market Forecast
- 10.2.3 APAC Market Forecast
- 10.2.4 Europe Market Forecast
- 10.2.5 Middle East & Africa Market Forecast
- 10.3 Americas Forecast by Countries
- 10.3.1 United States Market Forecast
- 10.3.2 Canada Market Forecast
- 10.3.3 Mexico Market Forecast
- 10.3.4 Brazil Market Forecast
- 10.4 APAC Forecast by Countries
- 10.4.1 China Market Forecast
- 10.4.2 Japan Market Forecast
- 10.4.3 Korea Market Forecast
- 10.4.4 Southeast Asia Market Forecast
- 10.4.5 India Market Forecast
- 10.4.6 Australia Market Forecast
- 10.5 Europe Forecast by Countries
- 10.5.1 Germany Market Forecast
- 10.5.2 France Market Forecast
- 10.5.3 UK Market Forecast
- 10.5.4 Italy Market Forecast
- 10.5.5 Russia Market Forecast
- 10.5.6 Spain Market Forecast
- 10.6 Middle East & Africa Forecast by Countries
- 10.6.1 Egypt Market Forecast
- 10.6.2 South Africa Market Forecast
- 10.6.3 Israel Market Forecast
- 10.6.4 Turkey Market Forecast
- 10.6.5 GCC Countries Market Forecast
- 10.7 Global Cancer Biologics Forecast by Type
- 10.8 Global Cancer Biologics Forecast by Application
11 Key Players Analysis
- 11.1 Roche
- 11.1.1 Company Details
- 11.1.2 Cancer Biologics Product Offered
- 11.1.3 Roche Cancer Biologics Revenue, Gross Margin and Market Share (2017-2019)
- 11.1.4 Main Business Overview
- 11.1.5 Roche News
- 11.2 Novartis
- 11.2.1 Company Details
- 11.2.2 Cancer Biologics Product Offered
- 11.2.3 Novartis Cancer Biologics Revenue, Gross Margin and Market Share (2017-2019)
- 11.2.4 Main Business Overview
- 11.2.5 Novartis News
- 11.3 Eli Lilly
- 11.3.1 Company Details
- 11.3.2 Cancer Biologics Product Offered
- 11.3.3 Eli Lilly Cancer Biologics Revenue, Gross Margin and Market Share (2017-2019)
- 11.3.4 Main Business Overview
- 11.3.5 Eli Lilly News
- 11.4 Sanofi
- 11.4.1 Company Details
- 11.4.2 Cancer Biologics Product Offered
- 11.4.3 Sanofi Cancer Biologics Revenue, Gross Margin and Market Share (2017-2019)
- 11.4.4 Main Business Overview
- 11.4.5 Sanofi News
- 11.5 Celgene
- 11.5.1 Company Details
- 11.5.2 Cancer Biologics Product Offered
- 11.5.3 Celgene Cancer Biologics Revenue, Gross Margin and Market Share (2017-2019)
- 11.5.4 Main Business Overview
- 11.5.5 Celgene News
- 11.6 Pfizer
- 11.6.1 Company Details
- 11.6.2 Cancer Biologics Product Offered
- 11.6.3 Pfizer Cancer Biologics Revenue, Gross Margin and Market Share (2017-2019)
- 11.6.4 Main Business Overview
- 11.6.5 Pfizer News
- 11.7 Bayer
- 11.7.1 Company Details
- 11.7.2 Cancer Biologics Product Offered
- 11.7.3 Bayer Cancer Biologics Revenue, Gross Margin and Market Share (2017-2019)
- 11.7.4 Main Business Overview
- 11.7.5 Bayer News
- 11.8 Johnson & Johnson
- 11.8.1 Company Details
- 11.8.2 Cancer Biologics Product Offered
- 11.8.3 Johnson & Johnson Cancer Biologics Revenue, Gross Margin and Market Share (2017-2019)
- 11.8.4 Main Business Overview
- 11.8.5 Johnson & Johnson News
- 11.9 Bristol-Myers Squibb
- 11.9.1 Company Details
- 11.9.2 Cancer Biologics Product Offered
- 11.9.3 Bristol-Myers Squibb Cancer Biologics Revenue, Gross Margin and Market Share (2017-2019)
- 11.9.4 Main Business Overview
- 11.9.5 Bristol-Myers Squibb News
- 11.10 Merck
- 11.10.1 Company Details
- 11.10.2 Cancer Biologics Product Offered
- 11.10.3 Merck Cancer Biologics Revenue, Gross Margin and Market Share (2017-2019)
- 11.10.4 Main Business Overview
- 11.10.5 Merck News
- 11.11 Amgen
12 Research Findings and Conclusion
Cancer Biologic is a medicinal preparation created by a biological process, it is used to treatment and remission cancer symptoms.
According to this study, over the next five years the Cancer Biologics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Cancer Biologics business, shared in Chapter 3.
This report presents a comprehensive overview, market shares and growth opportunities of Cancer Biologics market by product type, application, key companies and key regions.
This study considers the Cancer Biologics value generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Monoclonal Antibodies
Vaccines
Others
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hospitals
Clinics
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Roche
Novartis
Eli Lilly
Sanofi
Celgene
Pfizer
Bayer
Johnson & Johnson
Bristol-Myers Squibb
Merck
Amgen
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Cancer Biologics market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Cancer Biologics market by identifying its various subsegments.
Focuses on the key global Cancer Biologics players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Cancer Biologics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Cancer Biologics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.